Latest news with #preclinical
Yahoo
a day ago
- Health
- Yahoo
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
Highly selective targeting in Tg AD mouse model improved short-term memory and reduced plaque burden SEATTLE, July 28, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). "We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic," said Valerie Daggett, Ph.D., CEO and Founder of AltPep. "Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers." Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, "Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD." Poster Presentation Details: Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formationPoster #: 104011Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDTLocation: Exhibit Hall DE The poster will also be available in the "Scientific Publications" section of the AltPep website under "Presentations" at Select preclinical data show SOBIN-AD: binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, "These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic." About AltPep CorporationAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. About SOBIN Therapeutics and SOBA DiagnosticsSOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. For more information, please visit and follow us on LinkedIn. View source version on Contacts Media Contact: Susan SharpeLinnden Communicationssusan@
National Post
a day ago
- Health
- National Post
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
Article content SEATTLE — AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). Article content 'We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic,' said Valerie Daggett, Ph.D., CEO and Founder of AltPep. 'Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers.' Article content Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, 'Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD.' Article content Article content Poster #: Article content 104011 Article content Article content Date / Time: Article content Monday, July 28, 2025: 7:30 AM – 4:15 PM EDT Article content Article content Location: Article content Exhibit Hall DE Article content The poster will also be available in the 'Scientific Publications' section of the AltPep website under 'Presentations' at Article content Select preclinical data show SOBIN-AD: Article content binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Article content Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, 'These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic.' Article content About AltPep Corporation Article content AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Article content Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content
Yahoo
2 days ago
- Business
- Yahoo
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING, July 28, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the "BioMice" sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Preclinical Products and Services: info@ Antibody assets and platforms: BD-Licensing@ Media: pr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
12-07-2025
- Business
- Associated Press
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ('Onco' or the 'Company') is pleased to announce that it has entered into a services agreement with Redwood AI Inc. (Redwood AI). This collaboration marks continued advancement of Onco's mission to accelerate the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound (the 'Technology') and to extend its proprietary knowledge through discovery. This proprietary compound aims to target a range of solid tumours by enhancing sensitivity to radiation and DNA-damaging chemotherapies, offering the potential to exploit specific genetic susceptibilities in cancer. Through this agreement with Redwood AI, Onco gains access to Redwood AI's AI-driven chemistry tools that have the potential to unlock critical efficiencies in drug development, thereby carrying the potential to reduce synthesis complexity, refine compound design, and expand the pipeline of viable analogs. This effort is aimed at reinforcing Onco's technical capabilities at a crucial preclinical phase, with the goal of improving scalability, safety, and discovery precision. Under the scope of the agreement, Redwood AI will provide multi-pronged support across synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the Technology and its structural analogs. This includes independent reviews of third-party chemistry proposals and the use of Redwood's proprietary in-silico modelling tools. In simpler terms, these efforts are intended to deepen Onco's understanding of its Technology by supporting structure-based refinement and mechanistic insight. These efforts are part of Onco's broader strategy to efficiently progress toward First-in-Human studies. Redwood AI is a Vancouver-based artificial intelligence company harnessing artificial intelligence to accelerate drug synthesis and development. Founded by a team with deep roots in chemistry, AI, and drug manufacturing, including origins from Stanford1, Redwood AI is focused on overcoming one of the pharmaceutical industry's most persistent challenges - drug synthesis. By automating a substantial portion of the traditionally manual steps involved in synthesis, Redwood's technology aims to support more accurate, scalable, and cost-effective drug creation, with the goal of helping research teams move from discovery to development faster and with greater efficiency. 'The pace of innovation in cancer therapeutics depends on how quickly we can turn complex data into actionable decisions. Redwood AI's platform has the potential to enable us to explore synthesis strategies, evaluate risks, and optimize compound design with greater speed and precision. This kind of insight not only strengthens our scientific direction but also has the potential to accelerate our timeline towards clinical trials,' stated Thomas O'Shaughnessy, CEO of Onco-Innovations. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 [email protected] Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 1 SOURCE: Onco-Innovations Limited press release
Associated Press
10-06-2025
- Business
- Associated Press
Cryptobiotix Announces Its Next Evolutionary Step with Its Biobank Initiative to Accelerate Microbiome Innovation
06/10/2025, Ghent, Belgium // PRODIGY: Feature Story // Cryptobiotix, a next-generation preclinical research organization pioneering microbiome modeling through its proprietary SIFR platform, announces the launch of its biobank, marking the next phase in its continuous evolution. Co-founders Aurélien Baudot and Dr. Pieter Van den Abbeele founded Cryptobiotix to solve a critical gap in the field: the dreaded Valley of Death. Traditional preclinical testing is still slow or inaccurate, this could lead not only to delays but ultimately threaten the overall product development and launch. Now, with the launch of its biobank, the company is not just optimizing that core mission. It's redefining what's possible in microbiome research. 'We've always focused on delivering actionable insights, with the highest standards of scientific integrity, all while keeping to the tight deadlines our clients require,' says Baudot. 'We already had a streamlined process, but the biobank takes it to the next level. It's a small internal improvement, but one that has an exponential impact on our clients' workflows.' The Cryptobiotix biobank is more than just a freezer. It is a storage solution where cryo-stabilized gut microbiome samples are sourced, characterized, and stored under proprietary conditions that preserve both structure and function. This allows clients to build or tap into pre-qualified, pre-characterized microbiome samples instantly, bypassing weeks (sometimes months) of sourcing delays. In typical studies, donor sourcing can extend project timelines by two to eight weeks. But now, with tailored microbiome 'vaults' built to client specifications, those timelines shrink dramatically. Beyond speed, the biobank dramatically improves data granularity. Instead of working with random microbiomes, Cryptobiotix clients can now access specific metadata, such as diet, delivery method, age, country of origin, and more, to correlate clinical results to individual microbiome traits. 'It gives us immediate access to not just a 'baby microbiome,'' explains Dr. Van den Abbeele. 'It provides us access to a C-section baby, breastfed, and born in a specific country. This kind of clarity allows our partners to refine their experiment to the specific needs of their own business.' This opens the door for better responder/non-responder analysis and more refined product design, all essential for consumer health companies, nutrition innovators, and pharma organizations. The biobank fits seamlessly into Cryptobiotix's ex vivo modular SIFR platform, which simulates the entire gastrointestinal tract to understand the interplay between test products and the gut microbiome across individuals. By combining high throughput with validated predictivity, the company reduces development time and risk for clients worldwide. Cryptobiotix's research and development have also expanded into disease-rate simulation, including antibiotic-induced dysbiosis, acute infections, and Clostridium difficile modeling, helping therapeutic developers understand how interventions behave in both healthy and disrupted microbiomes. The company's precision is unmatched, wherein clients get a clearer view of how interventions truly behave in humans. While the launch of the biobank is an exciting milestone for the Cryptobiotix team, it is a natural, incremental evolution in its long-term strategy. 'For us, this is a stepping stone,' the founders say. 'We're already leveraging the data generated to train smarter analytics because the real future lies in making sense of complex microbiome datasets in ways the industry hasn't seen before.' Cryptobiotix is already exploring how its biobank can support longitudinal sample tracking, enabling comparisons of the same microbiome over time, even as donors' diets or health statuses change. This could offer clients unprecedented insights into microbiome stability, intervention reproducibility, and formulation refinements. With its cryo-stabilization method, perfected through hundreds of iterations, Cryptobiotix ensures the microbiome samples stored in its biobank retain their identity, empowering clients to revisit, reuse, and retest on demand. Media Contact Name: Cryptobiotix Team Email: [email protected] There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation.
